Yeap, I jinxed us. In fact, I jinxed the entire market. I had mentioned Amgen’s (AMGN, $57.41, down $1.33) eight-day winning streak yesterday and that quickly came to a halt just like the rest of the market’s momentum. The March 60 calls (YAACL, $1.70, down $0.50) were recommended on FebruaryRead more